|
| 37003269 | SGLT2 inhibitors in older adults: overcoming the age barrier. | | 2023 |
| 32971039 | Improving management of diabetic kidney disease: will GLP-1 receptor agonists have a role? | Lancet Diabetes and Endocrinology,The | 2020 |
| 32006520 | Evidence-based prescribing of diabetes medications: are we getting closer? | Lancet Diabetes and Endocrinology,The | 2020 |
| 32162273 | Glucokinase Activators for Type 2 Diabetes: Challenges and Future Developments. | Drugs | 2020 |
| 31251092 | Phenotypic characteristics and risk factors in a multi-ethnic cohort of young adults with type 2 diabetes. | Current Medical Research and Opinion | 2019 |
| 31189518 | IDegLira: combining efficacy, durability, and convenience? | Lancet Diabetes and Endocrinology,The | 2019 |
| 29652101 | Switching from sitagliptin to liraglutide to manage patients with type 2 diabetes in the UK: A long-term cost-effectiveness analysis. | Diabetes, Obesity and Metabolism | 2018 |
| 28847479 | Type 2 diabetes in adolescents and young adults. | Lancet Diabetes and Endocrinology,The | 2018 |
| 29397375 | Once-weekly GLP-1R agonists: moving the goal posts. | Lancet Diabetes and Endocrinology,The | 2018 |
| 28162147 | Prevalence and Associations of Obstructive Sleep Apnea in South Asians and White Europeans with Type 2 Diabetes: A Cross-Sectional Study. | Journal of Clinical Sleep Medicine | 2017 |
| 28433343 | Guidelines for type 2 diabetes: keeping a finger on the pulse. | Lancet Diabetes and Endocrinology,The | 2017 |
| 28432748 | Future challenges and therapeutic opportunities in type 2 diabetes: Changing the paradigm of current therapy. | Diabetes, Obesity and Metabolism | 2017 |
| 28594570 | Obstructive Sleep Apnea and Retinopathy in Patients with Type 2 Diabetes. A Longitudinal Study. | American Journal of Respiratory and Critical Care Medicine | 2017 |
| 28409160 | Peripheral and Autonomic Neuropathy in South Asians and White Caucasians with Type 2 Diabetes Mellitus: Possible Explanations for Epidemiological Differences. | Journal of Diabetes Research | 2017 |
| 26849483 | Perceptions of diabetes control among physicians and people with type 2 diabetes uncontrolled on basal insulin in Sweden, Switzerland, and the United Kingdom. | Current Medical Research and Opinion | 2016 |
| 26809680 | Future glucose-lowering drugs for type 2 diabetes. | Lancet Diabetes and Endocrinology,The | 2016 |
| 27339889 | Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus. | Nature Reviews Endocrinology | 2016 |
| 26907851 | Consequences of delaying treatment intensification in type 2 diabetes: evidence from a UK database. | Current Medical Research and Opinion | 2016 |
| 27263866 | Perceptions of diabetes control among people with type 2 diabetes treated with basal insulin in Sweden, Switzerland, and the United Kingdom. | Current Medical Research and Opinion | 2016 |
| 26940866 | Health and population effects of rare gene knockouts in adult humans with related parents. | Science | 2016 |
| 26331592 | NICE guidelines for Type 2 diabetes: revised but still not fit for purpose. | Diabet Med | 2015 |
| 25614693 | Treatment with the dipeptidyl peptidase-4 inhibitor linagliptin or placebo followed by glimepiride in patients with type 2 diabetes with moderate to severe renal impairment: a 52-week, randomized, double-blind clinical trial. | Diabetes Care | 2015 |
| 25772585 | NICE draft type 2 diabetes guidelines: a cause for concern. | Lancet Diabetes and Endocrinology,The | 2015 |
| 25351273 | Linagliptin for the treatment of type 2 diabetes mellitus: a drug safety evaluation. | Expert Opinion on Drug Safety | 2015 |
| 25308775 | Novel therapeutics for type 2 diabetes: insulin resistance. | Diabetes, Obesity and Metabolism | 2015 |
| 26361231 | Dipeptidyl peptidase-4 inhibitors in triple oral therapy regimens in patients with type 2 diabetes mellitus. | Current Medical Research and Opinion | 2015 |
| 26003754 | In defence of NICE draft type 2 diabetes guidelines--Author's reply. | Lancet Diabetes and Endocrinology,The | 2015 |
| 26254116 | The revised NICE draft guideline for type 2 diabetes: still a long way to go. | Lancet Diabetes Endocrinol | 2015 |
| 24509480 | Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. | Nat Genet | 2014 |
| 29872460 | A Patient-level Analysis of Efficacy and Hypoglycaemia Outcomes Across Treat-to-target Trials with Insulin Glargine Added to Oral Antidiabetes Agents in People with Type 2 Diabetes. | European Endocrinology | 2014 |
| 25301180 | Empagliflozin for the treatment of type 2 diabetes. | Expert Opinion on Pharmacotherapy | 2014 |
| 24461123 | Linagliptin for elderly patients with type 2 diabetes - Authors' reply. | Lancet, The | 2014 |
| 24169807 | Linagliptin added to sulphonylurea in uncontrolled type 2 diabetes patients with moderate-to-severe renal impairment. | | 2014 |
| 23949559 | Risk of breast cancer by individual insulin use: an international multicenter study. | Diabetes Care | 2014 |
| 24438528 | Genetic variants conferring susceptibility to Alzheimer's disease in the general population; do they also predispose to dementia in Down's syndrome. | BMC Research Notes | 2014 |
| 24188493 | The relationship between high-sensitivity CRP and polyclonal free light chains as markers of inflammation in chronic disease. | International Journal of Laboratory Hematology | 2014 |
| 24237939 | Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis. | Diabetes, Obesity and Metabolism | 2014 |
| 24865132 | Safety and efficacy of the dipeptidyl peptidase-4 inhibitor linagliptin in elderly patients with type 2 diabetes: a comprehensive analysis of data from 1331 individuals aged â¿¥ 65 years. | Diabetes, Obesity and Metabolism | 2014 |
| 24548693 | Incidence, worry and discussion about dosing irregularities and self-treated hypoglycaemia amongst HCPs and patients with type 2 diabetes: results from the UK cohort of the Global Attitudes of Patient and Physicians (GAPP2) survey. | International Journal of Clinical Practice | 2014 |
| 24795251 | Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. | Lancet Diabetes and Endocrinology,The | 2014 |
| 24703047 | Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. | Lancet Diabetes Endocrinol | 2014 |
| 24742658 | Elevated serum free light chains predict cardiovascular events in type 2 diabetes. | Diabetes Care | 2014 |
| 25073479 | What factors influence concordance with medications? Findings from the U.K. Asian Diabetes study. | Diabetic Medicine | 2014 |
| 24622320 | SGLT inhibitors in management of diabetes. | Lancet Diabetes and Endocrinology,The | 2013 |
| 23952328 | Increasing awareness of hypoglycaemia in patients with type 2 diabetes treated with oral agents. | Current Medical Research and Opinion | 2013 |
| 23949898 | Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy. | Clin Drug Investig | 2013 |
| 23948125 | Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial. | Lancet, The | 2013 |
| 24113667 | Impact of sodium glucose cotransporter 2 inhibitors on weight in patients with type 2 diabetes mellitus. | | 2013 |
| 24062320 | Obstructive sleep apnea and diabetic nephropathy: a cohort study. | Diabetes Care | 2013 |
| 23842433 | Cardiovascular benefits of incretins. | BMJ, The | 2013 |